Next Generation Therapeutics for Androgenetic Alopecia
January 2026
in “
OSF Preprints (OSF Preprints)
”
androgenetic alopecia AGA PROTAC androgen receptor AR degradation GT20029 topical AR-PROTAC AR antagonism genetic predisposition pre-miniaturization biomarkers stem-cell biology dermal papilla senescence perifollicular fibrosis niche-engineering stabilization phase reversal phase maintenance phase hair loss baldness
TLDR A new treatment plan for hair loss combines targeted therapies and regenerative strategies to stabilize, reverse, and maintain hair growth.
This paper introduces a comprehensive therapeutic framework for androgenetic alopecia (AGA) that combines PROTAC-mediated androgen receptor (AR) degradation with regenerative and micro-environmental strategies. It highlights GT20029 as a topical AR-PROTAC and compares its degradation effects to antagonism. The study evaluates early-intervention models based on genetic predisposition and pre-miniaturization biomarkers, integrating stem-cell biology, dermal papilla senescence, perifollicular fibrosis, and niche-engineering into a three-phase protocol: stabilization, reversal, and maintenance. The paper also proposes a development timeline for therapies and testable hypotheses to guide future research and clinical applications in AGA treatment.
